At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,648 enrolled
Drug / intervention
Rimegepant +1 moredrug
Likely dose
Rimegepant 75mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BHV3000-310: Phase 3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine
In Brief
A Phase 3 clinical trial evaluating Rimegepant and Placebo for Acute Migraine. Completed, enrolled 1,648 participants across 90 sites in 2 countries.
Detailed Summary
This trial is to determine whether BHV3000 (rimegepant) 75mg is safe and effictive as a treatment for acute migraine in Chinese and Korean patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Migraine
CountriesChina, South Korea
CollaboratorsBioShin Limited
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartOct 2020
Primary CompletionNov 2021
Study CompletionDec 2021
TodayJul 2026
First PostedOct 5, 2020
Enrollment StartOct 22, 2020
Primary CompletionNov 24, 2021
Study CompletionDec 16, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.7 years ago
Interventions
Rimegepantdrug
One 75mg orally disintegrating tablet
Placebodrug
Matching placebo